cancer drugs

Gilead to Buy Forty Seven for $4.9B
M&A

Gilead to Buy Forty Seven for $4.9B

The deal adds to Gilead's presence in immuno-oncology, an approach to treating cancer that harnesses the body's immune system.
By Lauren Muskett | March 2, 2020
Read More
Merck, Sanofi in Deals for Cancer Drug Firms
M&A

Merck, Sanofi in Deals for Cancer Drug Firms

The pharma giants each announced they would buy smaller drugmakers to expand cancer-treatment franchises.
By Lauren Muskett | December 9, 2019
Read More
Bristol-Myers to Buy Big Pharma Rival Celgene
M&A

Bristol-Myers to Buy Big Pharma Rival Celgene

The $74 billion deal could create the fourth-largest U.S. pharma firm, with a portfolio that includes nine blockbuster drugs.
By Matthew Heller | January 3, 2019
Read More
Glaxo Makes $5.1B Move Into Cancer Drugs
Strategy

Glaxo Makes $5.1B Move Into Cancer Drugs

The acquisition of Tesaro fits Glaxo's focus on gene-based therapies but investors are concerned it is paying too steep a price.
By Matthew Heller | December 3, 2018
Read More
J&J Gets Boost From Strong Cancer Drug Sales
Financial Performance

J&J Gets Boost From Strong Cancer Drug Sales

The company's Q3 earnings beat estimates but "it remains too early to call for a broad recovery" in the medical-device and consumer businesses.
By Matthew Heller | October 16, 2018
Read More
Roche Takes Full Control of Genomic Profiler
Strategy

Roche Takes Full Control of Genomic Profiler

The $2.4 billion purchase of 44% of Foundation Medicine raises Roche's bet on the development of personalized cancer treatments and care.
By Matthew Heller | June 19, 2018
Read More
Takeda Buys Ariad in $5.2B Cancer Drug Bet
Strategy

Takeda Buys Ariad in $5.2B Cancer Drug Bet

The Japanese drug giant is paying a 75% premium for Ariad to "transform our global solid tumor franchise."
By Matthew Heller | January 10, 2017
Read More